Judicious toggling of mTOR activity to combat insulin resistance and cancer: Current evidence and perspectives

• Main Authors: Ong, P.S, Wang, L.Z, Dai, X, Tseng, S.H, Loo, S.J, Sethi, G
• Other Authors: PHARMACOLOGY
• Format: Review
• Published: Frontiers Media S.A. 2020
• Subjects: 2 (4 amino 1 isopropyl 1h pyrazolo[3,4 d]pyrimidin 3 yl) 1h indol 5 ol; 2 (4 hydroxyphenyl) 4 morpholinopyrido[3',2':4,5]furo[3,2 d]pyrimidine; 2 amino 8 [4 (2 hydroxyethoxy)cyclohexyl] 6 (6 methoxy 3 pyridinyl) 4 methylpyrido[2,3 d]pyrimidin 7(8h) one; 4 (4 amino 5 (7 methoxy 1h indol 2 yl)imidazo[5,1 f][1,2,4]triazin 7 yl)cyclohexanecarboxylic acid; 5 [2 (2,6 dimethylmorpholino) 4 morpholinopyrido[2,3 d]pyrimidin 7 yl] 2 methoxybenzenemethanol; 8 (6 methoxy 3 pyridinyl) 3 methyl 1 [4 (1 piperazinyl) 3 (trifluoromethyl)phenyl] 1h imidazo[4,5 c]quinolin 2(3h) one; alpha interferon; apitolisib; azd 8055; c 115; cc 233; dactolisib; everolimus; mammalian target of rapamycin complex 1; mammalian target of rapamycin complex 2; mammalian target of rapamycin inhibitor; omipalisib; oxa 01; rapamycin; ridarolimus; sapanisertib; temsirolimus; torin1; unclassified drug; unindexed drug; vistusertib; way 600; wjd 008; wye 354; wye 687; xl 388; antineoplastic activity; cancer chemotherapy; cancer stem cell; carcinogenesis; diabetes mellitus; drug indication; drug structure; Hodgkin disease; human; insulin resistance; kidney carcinoma; large cell lymphoma; mantle cell lymphoma; mutation; neoplasm; neuroendocrine tumor; nonhodgkin lymphoma; nonhuman; ovary cancer; pathogenesis; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); protein expression; protein function; protein targeting; regulatory mechanism; Review; signal transduction; structure analysis
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/174246
• Institution: National University of Singapore

10.3389/fphar.2016.00395